In human pancreatic cancer cells—Suppress cell proliferation and induce apoptosis–Decrease expression of YAP at the mRNA and protein levels–Increase phosphorylation level of YAP–Decrease translocation of YAP to the nucleusIn human breast cancer cells—Decrease the expression of YAP target genes, including AREG, CTGF, and CYR61–Inactivate RhoA, activating LATS1 and induction of YAP phosphorylationIn human thyroid FTC238 cells—Increase expression of phosphorylated MST1/2, LATS1, and YAP–Decrease nuclear YAP and TAZ expression. This evidence concerns the gene CCN2 and pancreatic neoplasm.